ANAB

AnaptysBio, Inc. [ANAB] Stock Forecast

Q: What is AnaptysBio, Inc. stock symbol ?

AnaptysBio, Inc. is a US stock, located in San diego of Ca and trading under the symbol ANAB

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ANAB Stock Summary

Earnings are expected to rise 480.77% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Currently unprofitable, and not expected to turn profitable in the coming year

ANAB has less than 1 year of cash runway

Debt-to-Equity ratio of 1.33 is considered moderate, deeper research suggested.

Top ANAB Correlated Resources

ANAB

Top 10 Correlated ETFs

ANAB

Top 10 Correlated Stocks

ANAB

In the News

06:48 22 Mar 2023 ANAB

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

02:10 22 Mar 2023 ANAB

AnaptysBio to Participate in Upcoming November Investor Conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.

07:33 22 Mar 2023 ANAB

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

06:48 22 Mar 2023 ANAB

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

04:00 22 Mar 2023 ANAB

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT.

08:17 22 Mar 2023 ANAB

AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?

AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

12:48 22 Mar 2023 ANAB

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal

AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.

08:22 22 Mar 2023 ANAB

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. Imsidolimab was generally safe, well-tolerated, and no imsidolimab-related serious or severe adverse events.

07:24 22 Mar 2023 ANAB

AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the 2021 Jefferies London Healthcare Conference. The presentation will be available on Thursday, November 18, 2021, at 3:00 a.m. ET via https://wsw.com/webcast/jeff201/anab/1800252

03:06 22 Mar 2023 ANAB

AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis

AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules.

ANAB Financial details

Company Rating

Buy

Market Cap

608.9M

Income

-128.72M

Revenue

10.29M

Book val./share

9.31

Cash/share

15.67

Dividend

Dividend %

Employees

102

Optionable

Shortable

Yes

Earnings

02 May 2023

P/E

-4.76

Forward P/E

PEG

-0.41

P/S

59.58

P/B

2.34

P/C

1.39

P/FCF

-8.22

Quick Ratio

16.94

Current Ratio

17.16

Debt / Equity

1.33

LT Debt / Equity

0.07

EPS (TTM)

-4.58

EPS next Y

EPS next Q

-0.63

EPS this Y

116.59%

EPS next Y

EPS next 5Y

-77.07%

EPS last 5Y

12.82%

Revenue last 5Y

15.52%

Revenue Q/Q

426.53%

EPS Q/Q

-20.34%

SMA20

-14.28%

SMA50

-21.26%

SMA100

-18.15%

Inst Own

100%

Inst Trans

ROA

-21%

ROE

-44%

ROC

-0.2%

Gross Margin

12%

Oper. Margin

-1119%

Profit Margin

-1251%

Payout

Shs Outstand

27.93M

Shs Float

15.57M

Target Price

52W Range

18.2-32.435

52W High

-32%

52W Low

+20.89%

RSI

31.63

Rel Volume

0.64

Avg Volume

308.12K

Volume

196.45K

Perf Week

-2.73%

Perf Month

-15.72%

Perf Quarter

-15.33%

Perf Half Y

-10.97%

Beta

-0.101367

Volatility

0.52%, 1.6%

Prev Close

0.65%

Price

21.76

Change

-0.41%

ANAB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0.2	0.3	2.75	2.3	0.37
Net income per share	-2.5	-3.6	-0.73	-2.11	-4.57
Operating cash flow per share	-1.97	-2.57	-0.52	-1.67	-2.61
Free cash flow per share	-2.01	-2.6	-0.54	-1.67	-2.63
Cash per share	17.31	13.83	14.42	19.98	15.67
Book value per share	19.71	14.97	14.53	12.99	9.31
Tangible book value per share	19.71	14.97	14.53	12.99	9.31
Share holders equity per share	19.71	14.97	14.53	12.99	9.31
Interest debt per share	0.4	0.12	0.01	0.77	1.44
Market cap	1.57B	439.71M	586.99M	953.23M	872.83M
Enterprise value	1.47B	270.07M	336.88M	479.96M	820.98M
P/E ratio	-25.53	-4.52	-29.45	-16.49	-6.78
Price to sales ratio	314.78	54.96	7.83	15.09	84.85
POCF ratio	-32.45	-6.33	-41.46	-20.76	-11.86
PFCF ratio	-31.75	-6.25	-39.86	-20.77	-11.8
P/B Ratio	3.24	1.09	1.48	2.67	3.33
PTB ratio	3.24	1.09	1.48	2.67	3.33
EV to sales	293.71	33.76	4.49	7.6	79.81
Enterprise value over EBITDA	-24.52	-2.82	-17.39	-8.4	-7.8
EV to operating cash flow	-30.28	-3.88	-23.8	-10.45	-11.16
EV to free cash flow	-29.63	-3.84	-22.88	-10.46	-11.1
Earnings yield	-0.04	-0.22	-0.03	-0.06	-0.15
Free cash flow yield	-0.03	-0.16	-0.03	-0.05	-0.08
Debt to equity	0.05	0.07	0.05	0.8	1.33
Debt to assets	0.04	0.07	0.05	0.45	0.57
Net debt to EBITDA	1.76	1.77	12.91	8.28	0.49
Current ratio	19.89	12.79	20.01	34.4	17.16
Interest coverage	-40.39	-103.2	0	39.18	-5.46
Income quality	0.79	0.71	0.71	0.79	0.57
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	3.11	2.01	0.25	0.34	3.56
Research and developement to revenue	11.24	12.42	1.07	1.56	8.63
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0.01	0.04	0	0
Capex to revenue	-0.21	-0.1	-0.01	0	-0.03
Capex to depreciation	-3.37	-1.57	-1.02	0.01	-0.15
Stock based compensation to revenue	1.99	1.55	0.15	0.24	2.66
Graham number	33.29	34.81	15.45	24.82	30.93
ROIC	-0.24	-1.39	0.27	0.16	-0.25
Return on tangible assets	-0.12	-0.22	-0.05	-0.09	-0.21
Graham Net	16.4	12.71	13.69	9.53	3.3
Working capital	412.38M	348.2M	376.74M	537.78M	421.15M
Tangible asset value	486.37M	405.01M	396.73M	356.43M	262.1M
Net current asset value	411.58M	347.54M	376.74M	267.23M	98.93M
Invested capital	0.02	0.01	0	0.06	0.07
Average receivables	887.5K	87K	0	0	0
Average payables	3.88M	10.84M	10.23M	2.98M	2.26M
Average inventory	0	0	0	0	0
Days sales outstanding	12.7	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	28.74	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.13	-0.24	-0.05	-0.16	-0.49
Capex per share	-0.04	-0.03	-0.02	0	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0.04	0.04	0.04	0.05	0.24
Net income per share	-1.18	-1.31	-1.15	-1.18	-0.94
Operating cash flow per share	-0.92	-0.76	-0.86	-0.63	-0.38
Free cash flow per share	-0.87	-0.76	-0.86	-0.63	-0.39
Cash per share	19.91	18.24	15.68	15.66	15.67
Book value per share	12.95	11.93	10.79	9.81	9.31
Tangible book value per share	12.95	11.93	10.79	9.81	9.31
Share holders equity per share	12.95	11.93	10.79	9.81	9.31
Interest debt per share	0.76	0.92	0.93	0.92	0.84
Market cap	956.81M	685.62M	572.54M	721.65M	872.83M
Enterprise value	483.54M	539.8M	521.06M	682.94M	820.98M
P/E ratio	-7.35	-4.73	-4.4	-5.39	-8.26
Price to sales ratio	946.4	706.82	470.84	558.12	128.21
POCF ratio	-37.82	-32.63	-23.71	-40.66	-81.69
PFCF ratio	-39.98	-32.54	-23.63	-40.55	-80.37
P/B Ratio	2.68	2.07	1.88	2.6	3.33
PTB ratio	2.68	2.07	1.88	2.6	3.33
EV to sales	478.28	556.5	428.51	528.19	120.59
Enterprise value over EBITDA	-14.39	-17.51	-19.95	-25.5	-38.13
EV to operating cash flow	-19.11	-25.69	-21.58	-38.48	-76.83
EV to free cash flow	-20.2	-25.62	-21.51	-38.37	-75.6
Earnings yield	-0.03	-0.05	-0.06	-0.05	-0.03
Free cash flow yield	-0.03	-0.03	-0.04	-0.02	-0.01
Debt to equity	0.8	0.89	0.98	1.23	1.33
Debt to assets	0.45	0.47	0.5	0.55	0.57
Net debt to EBITDA	14.08	4.73	1.97	1.45	2.41
Current ratio	34.4	25.9	22.79	21.39	17.16
Interest coverage	21.49	-6.54	-4.74	-4.83	-6.11
Income quality	0.78	0.58	0.74	0.53	0.4
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	5.33	10.52	6.72	6.85	1.38
Research and developement to revenue	26.48	23.21	17.14	17.06	3.43
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	-0.05	0	0	0	0.02
Capex to revenue	1.35	-0.06	-0.06	-0.04	-0.03
Capex to depreciation	3.55	-0.1	-0.14	-0.09	-0.29
Stock based compensation to revenue	3.93	7.98	5.48	4.85	0.98
Graham number	18.55	18.74	16.74	16.17	14.01
ROIC	0.09	-0.11	-0.06	-0.06	-0.06
Return on tangible assets	-0.05	-0.06	-0.05	-0.05	-0.04
Graham Net	9.5	7.65	5.08	3.64	3.3
Working capital	537.78M	492.63M	432.94M	429.38M	421.15M
Tangible asset value	356.43M	330.75M	304.31M	277.62M	262.1M
Net current asset value	267.23M	217.99M	153.27M	109.56M	98.93M
Invested capital	0.06	0.06	0.07	0.07	0.07
Average receivables	380.5K	460.5K	977K	1.11M	590K
Average payables	3.73M	2.11M	2.03M	2.3M	2.9M
Average inventory	0	0	0	0	0
Days sales outstanding	0	85.45	76.46	82.13	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	1.05	1.18	1.1	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.09	-0.11	-0.11	-0.12	-0.1
Capex per share	0.05	0	0	0	-0.01

ANAB Frequently Asked Questions

What is AnaptysBio, Inc. stock symbol ?

AnaptysBio, Inc. is a US stock , located in San diego of Ca and trading under the symbol ANAB

Is AnaptysBio, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $32. The lowest prediction is $32 and the highest is $32

What is ANAB stock prediction ?

What is AnaptysBio, Inc. stock quote today ?

AnaptysBio, Inc. stock price is $21.76 today.

Is AnaptysBio, Inc. stock public?

Yes, AnaptysBio, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 308.12K
Market Capitalization 608.9M
Employee 102
CEO Mr. Daniel R. Faga
Headquarters San Diego,CA,US
IPO Date 2017-01-26
Website https://www.anaptysbio.com

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.